We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Labcorp (LH) Unveils Test for Preeclampsia in Pregnant Women
Read MoreHide Full Article
Laboratory Corporation of America Holdings, Inc., or Labcorp (LH - Free Report) , recently launched a new, FDA-cleared blood test for risk assessment and clinical management of severe preeclampsia. The preeclampsia is a life-threatening blood pressure disorder that occurs during pregnancy and the postpartum period.
The novel test detects two angiogenic biomarkers linked to preeclampsia — serum soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF). It was created by Thermo Fisher Scientific and was recognized as one of TIME Magazine's Best Inventions of 2023.
The recent development will bolster Labcorp Diagnostics Business.
More on the New Test
The test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia, the greatest cause of maternal and fetal mortality in the United States.
Image Source: Zacks Investment Research
The test result, when combined with other laboratory tests and clinical assessments, assists clinicians in determining which patients hospitalized for hypertensive disorders of pregnancy are at risk of developing severe preeclampsia within the next two weeks of the test. This was supported by the PRAECIS investigation, which investigated more than 1,000 pregnant women in 18 hospitals in the United States.
Significance of the Launch
Labcorp is happy to work with Thermo Fisher to deliver this innovative test, which is used in the second and third trimester of pregnancy to assess patients hospitalized for hypertensive diseases and gives doctors early and objective information to assist in the management of preeclampsia.
In line with Labcorp's mission to improve health and improve lives, this offering is another example of the company’s commitment to providing the most comprehensive and advanced menu of diagnostic tests while assisting patients and providers with clinically important and meaningful information to support better outcomes for parents and their newborns.
Industry Prospects
Per Value Market Research, the global demand for Preeclampsia Diagnostics Market is presumed to reach a market size of nearly $4177.69 million by 2030 from $1373.32 million in 2022 with a CAGR of 14.92%. The growing research and development of new tests to detect biomarkers that indicate preeclampsia are likely to promote market growth.
Notable Developments
In October 2023, Labcorp announced the launch and national availability of its blood biomarker test, Amyloid-Tau-Neurodegeneration (“ATN”) Profile. Physicians can use the test with patients who are being evaluated for possible Alzheimer's disease or other causes of cognitive impairment based on clinical observation and cognitive screenings.
The same month, Labcorp entered into an agreement with Baystate Health to acquire outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts. The transaction is expected to close in early 2024 and is subject to customary closing conditions and applicable regulatory approvals.
Price Performance
In the past six months, Labcorp’s shares have increased 4.1% against the industry’s 1.7% fall.
Zacks Rank and Key Picks
LH currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Acadia Healthcare (ACHC - Free Report) .
Universal Health Services, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 4.4% for 2024. UHS’s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 5.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UHS’ shares have inched up 6.2% in the past year compared with the industry’s 15.4% rise.
Integer Holdings, carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 36.9% in the past year against the industry’s 1.9% decline.
Acadia Healthcare, carrying a Zacks Rank of 2, has an estimated long-term growth rate of 10.4%. ACHC’s long-term earnings are expected to grow at 11.2%.
Acadia Healthcare’s shares have gained 4.3% in the past six months compared with the industry’s rise of 11.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Labcorp (LH) Unveils Test for Preeclampsia in Pregnant Women
Laboratory Corporation of America Holdings, Inc., or Labcorp (LH - Free Report) , recently launched a new, FDA-cleared blood test for risk assessment and clinical management of severe preeclampsia. The preeclampsia is a life-threatening blood pressure disorder that occurs during pregnancy and the postpartum period.
The novel test detects two angiogenic biomarkers linked to preeclampsia — serum soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF). It was created by Thermo Fisher Scientific and was recognized as one of TIME Magazine's Best Inventions of 2023.
The recent development will bolster Labcorp Diagnostics Business.
More on the New Test
The test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia, the greatest cause of maternal and fetal mortality in the United States.
The test result, when combined with other laboratory tests and clinical assessments, assists clinicians in determining which patients hospitalized for hypertensive disorders of pregnancy are at risk of developing severe preeclampsia within the next two weeks of the test. This was supported by the PRAECIS investigation, which investigated more than 1,000 pregnant women in 18 hospitals in the United States.
Significance of the Launch
Labcorp is happy to work with Thermo Fisher to deliver this innovative test, which is used in the second and third trimester of pregnancy to assess patients hospitalized for hypertensive diseases and gives doctors early and objective information to assist in the management of preeclampsia.
In line with Labcorp's mission to improve health and improve lives, this offering is another example of the company’s commitment to providing the most comprehensive and advanced menu of diagnostic tests while assisting patients and providers with clinically important and meaningful information to support better outcomes for parents and their newborns.
Industry Prospects
Per Value Market Research, the global demand for Preeclampsia Diagnostics Market is presumed to reach a market size of nearly $4177.69 million by 2030 from $1373.32 million in 2022 with a CAGR of 14.92%. The growing research and development of new tests to detect biomarkers that indicate preeclampsia are likely to promote market growth.
Notable Developments
In October 2023, Labcorp announced the launch and national availability of its blood biomarker test, Amyloid-Tau-Neurodegeneration (“ATN”) Profile. Physicians can use the test with patients who are being evaluated for possible Alzheimer's disease or other causes of cognitive impairment based on clinical observation and cognitive screenings.
The same month, Labcorp entered into an agreement with Baystate Health to acquire outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts. The transaction is expected to close in early 2024 and is subject to customary closing conditions and applicable regulatory approvals.
Price Performance
In the past six months, Labcorp’s shares have increased 4.1% against the industry’s 1.7% fall.
Zacks Rank and Key Picks
LH currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Acadia Healthcare (ACHC - Free Report) .
Universal Health Services, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 4.4% for 2024. UHS’s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 5.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UHS’ shares have inched up 6.2% in the past year compared with the industry’s 15.4% rise.
Integer Holdings, carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 36.9% in the past year against the industry’s 1.9% decline.
Acadia Healthcare, carrying a Zacks Rank of 2, has an estimated long-term growth rate of 10.4%. ACHC’s long-term earnings are expected to grow at 11.2%.
Acadia Healthcare’s shares have gained 4.3% in the past six months compared with the industry’s rise of 11.9%.